Levothyroxine Dosage Is Associated with Stability of Thyroid-stimulating Hormone Values - 20/02/14
, Gregory M. Garrison, MD, MS, Matthew E. Bernard, MDAbstract |
Objective |
In patients treated for hypothyroidism, the usual practice is to monitor thyroid-stimulating hormone values yearly once a therapeutic dosage of levothyroxine is determined. This study investigates whether there are any clinical predictors that could identify a subset of patients who might be monitored safely on a less frequent basis.
Methods |
With the use of a retrospective study design, 715 patients treated for hypothyroidism who had a normal (ie, therapeutic) thyroid-stimulating hormone value in 2006 while taking levothyroxine were identified. All thyroid-stimulating hormone values were then obtained through December 31, 2012. By using a Cox proportional hazard model, gender, age, body mass index, history of chronic autoimmune thyroiditis, initial thyroid-stimulating hormone level, and levothyroxine dose were analyzed for time to first abnormal thyroid-stimulating hormone value.
Results |
Age, gender, history of chronic autoimmune thyroiditis, and body mass index at the time of initial normal thyroid-stimulating hormone were not associated significantly with time to abnormal thyroid-stimulating hormone value. Levothyroxine dose >125 μg/day had an increased hazard ratio of 2.4 (95% confidence interval, 1.7-3.4; P < .0001) for time to first follow-up abnormal thyroid-stimulating hormone value, but dosages less than that did not increase the hazard ratio. One year after the initial normal thyroid-stimulating hormone value, 91.1% of patients taking ≤125 μg/day had a continued normal thyroid-stimulating hormone, whereas only 73.3% of patients taking >125 μg/day did. Transformed thyroid-stimulating hormone value (which represents a measure of how far the initial thyroid-stimulating hormone was from the midpoint of the normal range) also had an increased hazard ratio of 1.14 (95% confidence interval, 1.1-1.2; P < .0001) for time to first abnormal thyroid-stimulating hormone value.
Conclusions |
For patients receiving ≤125 μg/day of levothyroxine, we propose that a testing interval up to 2 years may be acceptable if their thyroid-stimulating hormone is well within the normal range.
Le texte complet de cet article est disponible en PDF.Keywords : Hypothyroidism, Hypothyroidism treatment, Levothyroxine dosage, Thyroid-stimulating hormone
Plan
| Funding: Provided by Mayo Clinic Department of Family Medicine. |
|
| Conflict of Interest: None. |
|
| Authorship: All authors had access to the data and played a role in writing this manuscript. |
Vol 127 - N° 3
P. 240-245 - mars 2014 Retour au numéro
Article précédent
- New Electrocardiographic Criteria to Differentiate Acute Pericarditis and Myocardial Infarction
- Xavier Rossello, Rob F. Wiegerinck, Joan Alguersuari, Alfredo Bardají, Fernando Worner, Mario Sutil, Andreu Ferrero, Juan Cinca
- ‘Krokodil’—A Designer Drug from Across the Atlantic, with Serious Consequences
- Dany V. Thekkemuriyi, Santhosh Gheevarghese John, Unnikrishnan Pillai
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?